IFPMA Adopts Revised Marketing Code
A revised Code of Pharmaceutical Marketing Practices was formally approved by the 17th General Assembly of the International Federation of Pharmaceutical Manufacturers Association, held in Malmo, Sweden, from August 31 to September 2.
The decision to carry out a complete revision of the text and format of the IFPMA code was taken by the association's Council in 1993, and a task force was established to advise on the revisions. Member associations were consulted on the proposed revised text in February 1994, and the Council adopted the final text of the code in June.
Revision of the code took into account discussions at the World Health Organization/Council for International Medical Sciences consultations on WHO Ethical Criteria for medicinal drug promotion, which took place in April 1993.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze